Advertisement
Screener

OPKO Health, Inc. (OPK) Goodwill, Foreign Currency Translation Gain (Loss)

1.5 / 5 stars · 26/87 Roast Me

OPKO Health, Inc. Goodwill, Foreign Currency Translation Gain (Loss)

OPKO Health, Inc. (OPK) reported Goodwill, Foreign Currency Translation Gain (Loss) of -$2.77 million for the 6-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.

Financial Statements › Income Statement › Other Income

us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2026-08-28

  • OPKO Health, Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2026-06-30 was -$753.00K, a 110.02% decline year-over-year.
  • OPKO Health, Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2026-03-31 was -$2.02M, a 154.84% decline year-over-year.
  • OPKO Health, Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-12-31 was $257.00K.
  • OPKO Health, Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-09-30 was -$153.00K, a 104.04% decline year-over-year.
  • OPKO Health, Inc. goodwill, foreign currency translation gain (loss) for fiscal 2025 was $11.30M.
  • OPKO Health, Inc. goodwill, foreign currency translation gain (loss) for fiscal 2024 was -$5.69M, a 320.46% decline from fiscal 2023.
  • OPKO Health, Inc. goodwill, foreign currency translation gain (loss) for fiscal 2023 was $2.58M.
  • OPKO Health, Inc. goodwill, foreign currency translation gain (loss) for fiscal 2022 was -$5.18M.
Period endGoodwill, Foreign Currency Translation Gain (Loss) 3 monthGoodwill, Foreign Currency Translation Gain (Loss) 6 monthGoodwill, Foreign Currency Translation Gain (Loss) 9 monthGoodwill, Foreign Currency Translation Gain (Loss) 12 monthGoodwill, Foreign Currency Translation Gain (Loss) 12 month as first filed
2026-06-30-$753.00K
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28
-$2.77M
10-Q/A · filed 2026-08-28
-$2.52M
derived: sum of 3 quarters · filed 2026-08-28
-$2.67M
derived: sum of 4 quarters · filed 2026-08-28
2026-03-31-$2.02M
10-Q/A · filed 2026-08-28
-$1.76M
derived: sum of 2 quarters · filed 2026-08-28
-$1.92M
derived: sum of 3 quarters · filed 2026-08-28
$5.60M
derived: sum of 4 quarters · filed 2026-08-28
2025-12-31$257.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$104.00K
derived: sum of 2 quarters · filed 2026-02-26
$7.62M
derived: sum of 3 quarters · filed 2026-02-26
$11.30M
10-K · filed 2026-02-26
2025-09-30-$153.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29
$7.36M
derived: sum of 2 quarters · filed 2025-10-29
$11.04M
10-Q · filed 2025-10-29
$4.43M
derived: sum of 4 quarters · filed 2026-02-26
2025-06-30$7.51M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31
$11.20M
10-Q · filed 2025-07-31
$4.58M
derived: sum of 3 quarters · filed 2026-02-26
$8.37M
derived: sum of 4 quarters · filed 2026-02-26
2025-03-31$3.69M
10-Q · filed 2025-05-01
-$2.93M
derived: sum of 2 quarters · filed 2026-02-26
$855.00K
derived: sum of 3 quarters · filed 2026-02-26
$346.00K
derived: sum of 4 quarters · filed 2026-02-26
2024-12-31-$6.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$2.83M
derived: sum of 2 quarters · filed 2026-02-26
-$3.34M
derived: sum of 3 quarters · filed 2026-02-26
-$5.69M
10-K · filed 2026-02-26
2024-09-30$3.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$3.28M
derived: sum of 2 quarters · filed 2024-11-07
$926.00K
10-Q · filed 2024-11-07
$4.73M
derived: sum of 4 quarters · filed 2025-03-03
2024-06-30-$509.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
-$2.86M
10-Q · filed 2024-08-07
$943.00K
derived: sum of 3 quarters · filed 2025-03-03
-$1.98M
derived: sum of 4 quarters · filed 2025-03-03
2024-03-31-$2.35M
10-Q · filed 2024-05-07
$1.45M
derived: sum of 2 quarters · filed 2025-03-03
-$1.47M
derived: sum of 3 quarters · filed 2025-03-03
-$1.47M
derived: sum of 4 quarters · filed 2025-03-03
2023-12-31$3.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
$885.00K
derived: sum of 2 quarters · filed 2025-03-03
$879.00K
derived: sum of 3 quarters · filed 2025-03-03
$2.58M
10-K · filed 2025-03-03
$2.58M
10-K · filed 2024-03-01
2023-09-30-$2.92M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
-$2.92M
derived: sum of 2 quarters · filed 2023-11-06
-$1.22M
10-Q · filed 2023-11-06
$6.56M
derived: sum of 4 quarters · filed 2024-03-01
2023-06-30-$6.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
$1.70M
10-Q · filed 2023-08-03
$9.48M
derived: sum of 3 quarters · filed 2024-03-01
$4.06M
derived: sum of 4 quarters · filed 2024-03-01
2023-03-31$1.70M
10-Q · filed 2023-05-03
$9.49M
derived: sum of 2 quarters · filed 2024-03-01
$4.06M
derived: sum of 3 quarters · filed 2024-03-01
$149.85M
derived: sum of 4 quarters · filed 2024-03-01
2022-12-31$7.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01
$2.36M
derived: sum of 2 quarters · filed 2024-03-01
$148.15M
derived: sum of 3 quarters · filed 2024-03-01
-$5.18M
10-K · filed 2024-03-01
2022-09-30-$5.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$140.37M
derived: sum of 2 quarters · filed 2022-11-08
-$12.97M
10-Q · filed 2022-11-08
-$166.94M
derived: sum of 4 quarters · filed 2023-02-27
2022-06-30$145.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$7.54M
10-Q · filed 2022-08-04
-$161.52M
derived: sum of 3 quarters · filed 2023-02-27
-$164.30M
derived: sum of 4 quarters · filed 2023-02-27
2022-03-31-$153.33M
10-Q · filed 2022-05-09
-$307.31M
derived: sum of 2 quarters · filed 2023-02-27
-$310.09M
derived: sum of 3 quarters · filed 2023-02-27
-$308.89M
derived: sum of 4 quarters · filed 2023-02-27
2021-12-31-$153.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
-$156.76M
derived: sum of 2 quarters · filed 2023-02-27
-$155.56M
derived: sum of 3 quarters · filed 2023-02-27
-$160.00M
10-K · filed 2023-02-27
2021-09-30-$2.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28
-$1.59M
derived: sum of 2 quarters · filed 2021-10-28
-$6.03M
10-Q · filed 2021-10-28
-$1.22M
derived: sum of 4 quarters · filed 2022-03-01
2021-06-30$1.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29
-$3.24M
10-Q · filed 2021-07-29
$1.56M
derived: sum of 3 quarters · filed 2022-03-01
$5.76M
derived: sum of 4 quarters · filed 2022-03-01
2021-03-31-$4.44M
10-Q · filed 2021-04-28
$367.00K
derived: sum of 2 quarters · filed 2022-03-01
$4.56M
derived: sum of 3 quarters · filed 2022-03-01
$6.58M
derived: sum of 4 quarters · filed 2022-03-01
2020-12-31$4.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$9.00M
derived: sum of 2 quarters · filed 2022-03-01
$11.02M
derived: sum of 3 quarters · filed 2022-03-01
$8.66M
10-K · filed 2022-03-01
2020-09-30$4.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29
$6.21M
derived: sum of 2 quarters · filed 2020-10-29
$3.85M
10-Q · filed 2020-10-29
$6.22M
derived: sum of 4 quarters · filed 2021-02-18
2020-06-30$2.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31
-$341.00K
10-Q · filed 2020-07-31
$2.03M
derived: sum of 3 quarters · filed 2021-02-18
-$2.02M
derived: sum of 4 quarters · filed 2021-02-18
2020-03-31-$2.36M
10-Q · filed 2020-05-06
$9.00K
derived: sum of 2 quarters · filed 2021-02-18
-$4.04M
derived: sum of 3 quarters · filed 2021-02-18
-$2.71M
derived: sum of 4 quarters · filed 2021-02-18
2019-12-31$2.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-18
-$1.68M
derived: sum of 2 quarters · filed 2021-02-18
-$357.00K
derived: sum of 3 quarters · filed 2021-02-18
-$2.03M
10-K · filed 2021-02-18
2019-09-30-$4.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
-$2.72M
derived: sum of 2 quarters · filed 2019-11-05
-$4.39M
10-Q · filed 2019-11-05
-$6.13M
derived: sum of 4 quarters · filed 2020-03-02
2019-06-30$1.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
-$351.00K
10-Q · filed 2019-08-07
-$2.09M
derived: sum of 3 quarters · filed 2020-03-02
-$2.69M
derived: sum of 4 quarters · filed 2020-03-02
2019-03-31-$1.67M
10-Q · filed 2019-05-08
-$3.41M
derived: sum of 2 quarters · filed 2020-03-02
-$4.01M
derived: sum of 3 quarters · filed 2020-03-02
-$9.67M
derived: sum of 4 quarters · filed 2020-03-02
2018-12-31-$1.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
-$2.34M
derived: sum of 2 quarters · filed 2020-03-02
-$8.00M
derived: sum of 3 quarters · filed 2020-03-02
-$5.21M
10-K · filed 2020-03-02
2018-09-30-$605.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
-$6.26M
derived: sum of 2 quarters · filed 2018-11-09
-$3.47M
10-Q · filed 2018-11-09
-$1.94M
derived: sum of 4 quarters · filed 2019-03-01
2018-06-30-$5.66M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
-$2.87M
10-Q · filed 2018-08-07
-$1.34M
derived: sum of 3 quarters · filed 2019-03-01
$2.16M
derived: sum of 4 quarters · filed 2019-03-01
2018-03-31$2.79M
10-Q · filed 2018-05-08
$4.32M
derived: sum of 2 quarters · filed 2019-03-01
$7.82M
derived: sum of 3 quarters · filed 2019-03-01
$13.90M
derived: sum of 4 quarters · filed 2019-03-01
2017-12-31$1.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
$5.02M
derived: sum of 2 quarters · filed 2019-03-01
$11.11M
derived: sum of 3 quarters · filed 2019-03-01
$12.50M
10-K · filed 2019-03-01
2017-09-30$3.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
$9.58M
derived: sum of 2 quarters · filed 2017-11-08
$10.97M
10-Q · filed 2017-11-08
2017-06-30$6.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08
$7.47M
10-Q · filed 2017-08-08
2017-03-31$1.39M
10-Q · filed 2017-05-10
2016-09-30$880.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
-$1.04M
derived: sum of 2 quarters · filed 2016-11-07
$2.89M
10-Q · filed 2016-11-07
2016-06-30-$1.92M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08
$2.01M
10-Q · filed 2016-08-08
2016-03-31$3.93M
10-Q · filed 2016-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
HARROW, INC. (HROW)United States$1.240B-42.77
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
Jaguar Health, Inc. (JAGX)United States$1.184B
Latigo Biotherapeutics, Inc. (LTGO)United States$1.176B
Avalyn Pharma Inc. (AVLN)United States$1.267B
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93